A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Latest Information Update: 21 Jan 2022
Price :
$35 *
At a glance
- Drugs Methylprednisolone (Primary) ; Prednisolone (Primary) ; Ruxolitinib (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Acronyms REACH-1
- Sponsors Incyte Corporation
- 14 Dec 2021 Results of AREG as a monitoring biomarker in our larger uhCG/EGF treated cohort and validate them in an independent cohort of patients with steroid-refractory aGVHD receiving ruxolitinib as second-line therapy in the REACH1 study presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 05 Aug 2020 Results published in the Blood
- 29 Jul 2020 Status changed from active, no longer recruiting to completed.